{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:32:03Z","timestamp":1792783923409,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Fondo de Investigaciones sanitarias","award":["PI16CIII\/00014"],"award-info":[{"award-number":["PI16CIII\/00014"]}]},{"name":"Fondo de Investigaciones sanitarias","award":["MPY 1347\/16"],"award-info":[{"award-number":["MPY 1347\/16"]}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.cmi.2020.05.037","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T02:10:35Z","timestamp":1591841435000},"page":"1481-1487","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":144,"title":["Antifungal therapeutic drug monitoring: focus on drugs without a clear recommendation"],"prefix":"10.1016","volume":"26","author":[{"given":"A.","family":"G\u00f3mez-L\u00f3pez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2020.05.037_bib1","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.cca.2019.01.023","article-title":"Advances in antifungal drug measurement by liquid chromatography-mass spectrometry","volume":"491","author":"Zheng","year":"2019","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.cmi.2020.05.037_bib2","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/myc.12585","article-title":"Efficacy and safety of amphotericin B lipid-based formulations\u2014a systematic review and meta-analysis","volume":"60","author":"Steimbach","year":"2017","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2020.05.037_bib3","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40265-013-0069-4","article-title":"Amphotericin B formulations: a comparative review of efficacy and toxicity","volume":"73","author":"Hamill","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.cmi.2020.05.037_bib4","first-page":"131","article-title":"Liposomal amphotericin B (ambisome(r)) at beginning of its third decade of clinical use","volume":"29","author":"Aversa","year":"2017","journal-title":"J\u00a0Chemother"},{"key":"10.1016\/j.cmi.2020.05.037_bib5","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1128\/AAC.46.3.828-833.2002","article-title":"Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (ambisome) and amphotericin B deoxycholate in humans","volume":"46","author":"Bekersky","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.05.037_bib6","first-page":"34","article-title":"Liposomes and lipid carriers in the treatment of microbial infections","volume":"74","author":"Bakker-Woudenberg","year":"1990","journal-title":"Scand J Infect Dis Suppl"},{"key":"10.1016\/j.cmi.2020.05.037_bib7","doi-asserted-by":"crossref","first-page":"e220","DOI":"10.1016\/j.ijid.2009.07.020","article-title":"Comparison between concentrations of amphotericin B in infected lung lesion and in uninfected lung tissue in a patient treated with liposomal amphotericin B (ambisome)","volume":"14","author":"Watanabe","year":"2010","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cmi.2020.05.037_bib8","first-page":"82","article-title":"Penetration of amphotericin B in human lung tissue after single liposomal amphotericin B (ambisome) infusion","volume":"17","author":"Demartini","year":"2005","journal-title":"J\u00a0Chemother"},{"key":"10.1016\/j.cmi.2020.05.037_bib9","doi-asserted-by":"crossref","first-page":"805","DOI":"10.4065\/mcp.2011.0247","article-title":"Current concepts in antifungal pharmacology","volume":"86","author":"Lewis","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cmi.2020.05.037_bib10","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1128\/AAC.02226-12","article-title":"Pharmacodynamics and dose\u2013response relationships of liposomal amphotericin B against different azole-resistant Aspergillus fumigatus isolates in a murine model of disseminated aspergillosis","volume":"57","author":"Seyedmousavi","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.05.037_bib11","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1128\/AAC.50.2.674-684.2006","article-title":"Pharmacokinetic\u2013pharmacodynamic comparison of amphotericin B (amb) and two lipid-associated amb preparations, liposomal amb and amb lipid complex, in murine candidiasis models","volume":"50","author":"Andes","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.05.037_bib12","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1080\/08982104.2016.1205087","article-title":"Ambisome: relationship between the pharmacokinetic characteristics acquired by liposomal formulation and safety\/efficacy","volume":"27","author":"Takemoto","year":"2017","journal-title":"J\u00a0Liposome Res"},{"key":"10.1016\/j.cmi.2020.05.037_bib13","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1348-0421.2006.tb03832.x","article-title":"Evaluation of antifungal pharmacodynamic characteristics of ambisome against Candida albicans","volume":"50","author":"Takemoto","year":"2006","journal-title":"Microbiol Immunol"},{"key":"10.1016\/j.cmi.2020.05.037_bib14","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1128\/AAC.50.3.935-942.2006","article-title":"Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases","volume":"50","author":"Hong","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.05.037_bib15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13054-015-0758-3","article-title":"Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: data from multinational defining antibiotic levels in intensive care unit (DALI) patients study","volume":"19","author":"Sinnollareddy","year":"2015","journal-title":"Crit Care"},{"key":"10.1016\/j.cmi.2020.05.037_bib16","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British society for medical mycology","volume":"69","author":"Ashbee","year":"2014","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2020.05.037_bib17","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/jac\/dku169","article-title":"Intra-abdominal penetration and pharmacodynamic exposure to fluconazole in three liver transplant patients with deep-seated candidiasis","volume":"69","author":"Pea","year":"2014","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2020.05.037_bib18","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13113","article-title":"Treatment of candida infections with fluconazole in adult liver transplant recipients: is TDM-guided dosing adaptation helpful?","volume":"21","author":"Righi","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.cmi.2020.05.037_bib19","series-title":"Astellas pharma US inc. March 2015. Cresemba\u00ae (isavuconazonium sulfate) prescribing information","year":"2015"},{"key":"10.1016\/j.cmi.2020.05.037_bib20","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2020.05.037_bib21","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.cmi.2020.05.037_bib22","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/cpdd.285","article-title":"Pharmacokinetic evaluation of cyp3a4-mediated drug-drug interactions of isavuconazole with rifampin, ketoconazole, midazolam, and ethinyl estradiol\/norethindrone in healthy adults","volume":"6","author":"Townsend","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.cmi.2020.05.037_bib23","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1128\/AAC.02819-15","article-title":"Population pharmacokinetics of isavuconazole from phase 1 and phase 3 (secure) trials in adults and target attainment in patients with invasive infections due to aspergillus and other filamentous fungi","volume":"60","author":"Desai","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.05.037_bib24","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00585-18","article-title":"Isavuconazole concentration in real-world practice: consistency with results from clinical trials","volume":"62","author":"Andes","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.05.037_bib25","doi-asserted-by":"crossref","first-page":"i44","DOI":"10.1093\/jac\/dkx448","article-title":"We can do better: a fresh look at echinocandin dosing","volume":"73","author":"Bader","year":"2018","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2020.05.037_bib26","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1345\/aph.1M237","article-title":"Echinocandins: the newest class of antifungals","volume":"43","author":"Sucher","year":"2009","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.cmi.2020.05.037_bib27","doi-asserted-by":"crossref","first-page":"i14","DOI":"10.1093\/jac\/dkx445","article-title":"What has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead","volume":"73","author":"Bassetti","year":"2018","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2020.05.037_bib28","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11908-016-0549-2","article-title":"Echinocandin resistance in Candida species: a review of recent developments","volume":"18","author":"Wiederhold","year":"2016","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.cmi.2020.05.037_bib29","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1128\/AAC.01584-09","article-title":"In\u00a0vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species","volume":"54","author":"Andes","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.05.037_bib30","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1128\/AAC.01430-10","article-title":"Use of pharmacokinetic\u2013pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia","volume":"55","author":"Andes","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.05.037_bib31","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01412-17","article-title":"The gastrointestinal tract is a major source of echinocandin drug resistance in a murine model of Candida glabrata colonization and systemic dissemination","volume":"61","author":"Healey","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.05.037_bib32","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1586\/14787210.2015.1028366","article-title":"Impact of special patient populations on the pharmacokinetics of echinocandins","volume":"13","author":"Muilwijk","year":"2015","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.cmi.2020.05.037_bib33","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2020.05.037_bib34","doi-asserted-by":"crossref","first-page":"4782","DOI":"10.1128\/AAC.01083-10","article-title":"Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients","volume":"55","author":"Troke","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.05.037_bib35","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1093\/jac\/dkw045","article-title":"Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis","volume":"71","author":"Jin","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2020.05.037_bib36","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/jac\/dkw099","article-title":"Utility of voriconazole therapeutic drug monitoring: a meta-analysis","volume":"71","author":"Luong","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2020.05.037_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jphotobiol.2018.07.023","article-title":"Photosensitisation by voriconazole-N-oxide results from a sequence of solvent and pH-dependent photochemical and thermal reactions","volume":"187","author":"Morliere","year":"2018","journal-title":"J\u00a0Photochem Photobiol B"},{"key":"10.1016\/j.cmi.2020.05.037_bib38","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01194-17","article-title":"Pharmacokinetic modeling of voriconazole to develop an alternative dosing regimen in children","volume":"62","author":"Gastine","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.05.037_bib39","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1517\/17425255.2013.794785","article-title":"Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections","volume":"9","author":"Lestner","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.cmi.2020.05.037_bib40","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.ijantimicag.2015.07.007","article-title":"In\u00a0vivo efficacy of voriconazole and posaconazole therapy in a novel invertebrate model of Aspergillus fumigatus infection","volume":"46","author":"Forastiero","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2020.05.037_bib41","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1046\/j.1439-0507.1999.00505.x","article-title":"Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole","volume":"42","author":"Glasmacher","year":"1999","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2020.05.037_bib42","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.2147\/IDR.S203579","article-title":"Comparative effectiveness of antifungal agents in patients with hematopoietic stem cell transplantation: a systematic review and network meta-analysis","volume":"12","author":"Su","year":"2019","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.cmi.2020.05.037_bib43","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1128\/AAC.37.4.778","article-title":"Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers","volume":"37","author":"Barone","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.05.037_bib44","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/clpt.2014.41","article-title":"Itraconazole and clarithromycin as ketoconazole alternatives for clinical cyp3a inhibition studies","volume":"95","author":"Ke","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cmi.2020.05.037_bib45","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00277-017-3196-2","article-title":"Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the infectious diseases working party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)","volume":"97","author":"Mellinghoff","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.cmi.2020.05.037_bib46","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12879-018-3055-3","article-title":"Utility of posaconazole therapeutic drug monitoring and assessment of plasma concentration threshold for effective prophylaxis of invasive fungal infections: a meta-analysis with trial sequential analysis","volume":"18","author":"Chen","year":"2018","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2020.05.037_bib47","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/179663a0","article-title":"Fluorinated pyrimidines, a new class of tumour-inhibitory compounds","volume":"179","author":"Heidelberger","year":"1957","journal-title":"Nature"},{"key":"10.1016\/j.cmi.2020.05.037_bib48","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/649858","article-title":"Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America","volume":"50","author":"Perfect","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2020.05.037_bib49","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1093\/cid\/ciw151","article-title":"Cryptococcal meningitis treatment strategies affected by the explosive cost of flucytosine in the United States: a cost-effectiveness analysis","volume":"62","author":"Merry","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2020.05.037_bib50","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1128\/AAC.11.2.244","article-title":"Bone marrow toxicity associated with 5-fluorocytosine therapy","volume":"11","author":"Kauffman","year":"1977","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.05.037_bib51","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/0002-9343(87)90691-7","article-title":"Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis","volume":"83","author":"Stamm","year":"1987","journal-title":"Am J Med"},{"key":"10.1016\/j.cmi.2020.05.037_bib52","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0272-2712(18)30729-7","volume":"7","author":"Flucytosine (5-fluorocytosine","year":"1987","journal-title":"Clin Lab Med"},{"key":"10.1016\/j.cmi.2020.05.037_bib53","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s40262-014-0147-0","article-title":"Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants","volume":"53","author":"Roberts","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cmi.2020.05.037_bib54","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.plabm.2017.05.002","article-title":"Performance evaluation of enzyme immunoassay for voriconazole therapeutic drug monitoring with automated clinical chemistry analyzers","volume":"8","author":"Jeon","year":"2017","journal-title":"Pract Lab Med"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X20303359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X20303359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:26:19Z","timestamp":1761117979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X20303359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":54,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1198743X20303359"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2020.05.037","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antifungal therapeutic drug monitoring: focus on drugs without a clear recommendation","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2020.05.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}